EP Patent

EP4169915A1 — Crystalline form of compound

Assigned to Shenzhen Forward Pharmaceuticals Co Ltd · Expires 2023-04-26 · 3y expired

What this patent protects

The present application relates to the crystalline form of the mesylate salt, the crystalline form of the hydrochloride salt and the crystalline form of the maleate salt of a compound of formula (I): The present application also relates to a method for treating non-s…

USPTO Abstract

The present application relates to the crystalline form of the mesylate salt, the crystalline form of the hydrochloride salt and the crystalline form of the maleate salt of a compound of formula (I): The present application also relates to a method for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation using the crystalline forms. The present application also relates to synthetic routes for the compound of formula (I).

Drugs covered by this patent

Patent Metadata

Patent number
EP4169915A1
Jurisdiction
EP
Classification
—
Expires
2023-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.